• PYR-41: Selective Inhibitor of Ubiquitin-Activating Enzym...

  2026-01-22

  PYR-41 is a selective ubiquitin-activating enzyme E1 inhibitor used to block ubiquitination, modulate the NF-κB signaling pathway, and dissect protein degradation mechanisms. This product demonstrates robust efficacy in cellular and animal models but exhibits partial nonspecificity and is not approved for clinical use. Its unique mechanistic profile makes it an essential tool for protein quality control and inflammation research.

• Axitinib (AG 013736): Data-Driven Solutions for Cancer As...

  2026-01-21

  This article delivers practical, scenario-based insights into using Axitinib (AG 013736) (SKU A8370) for reproducible, quantitative cell-based assays in cancer biology research. Drawing from current literature and real-world lab challenges, it illustrates how Axitinib’s validated specificity, solubility, and batch reliability can streamline assay design and data interpretation. The content empowers bench scientists to resolve common workflow obstacles while leveraging APExBIO’s trusted reagent quality.

• Scenario-Driven Solutions: Carfilzomib (PR-171) in Cancer...

  2026-01-21

  This article offers practical, evidence-backed guidance for biomedical researchers leveraging Carfilzomib (PR-171) (SKU A1933) in cell viability, proliferation, and cytotoxicity assays. Through real-world laboratory scenarios, we demonstrate how this irreversible proteasome inhibitor addresses reproducibility, sensitivity, and workflow challenges, positioning APExBIO’s Carfilzomib as a robust tool for cancer biology research.

• PYR-41: Selective Ubiquitin-Activating Enzyme E1 Inhibito...

  2026-01-20

  PYR-41 is a selective inhibitor of Ubiquitin-Activating Enzyme E1, used to block ubiquitination and interrogate the ubiquitin-proteasome system in cell and animal models. This article details its mechanism, experimental benchmarks, and research applications, establishing PYR-41 as a critical tool for protein degradation pathway research and inflammation studies.

• CB-5083: Unraveling Protein Homeostasis Disruption in Can...

  2026-01-20

  Explore how CB-5083, a selective p97 inhibitor, revolutionizes cancer research by disrupting protein homeostasis and inducing apoptosis. This article uniquely examines advanced mechanistic insights, translational impact, and new frontiers enabled by CB-5083.

• Translating Immunoproteasome Inhibition into Therapeutic ...

  2026-01-19

  This thought-leadership article explores the mechanistic, translational, and strategic dimensions of immunoproteasome LMP7 subunit targeting using ONX-0914 (PR-957). Drawing on recent findings—including the nuanced role of non-constitutive proteasome inhibition in synaptic plasticity—the piece guides translational researchers through advanced experimental applications, competitive context, and forward-looking research opportunities. By integrating mechanistic clarity, study evidence, and strategic positioning, the article delivers a comprehensive resource for leveraging ONX-0914 in autoimmune, inflammatory, and neurobiological disease models, and positions APExBIO as a provider of next-generation research tools.

• PYR-41 and the Ubiquitin-Proteasome System: Mechanistic I...

  2026-01-19

  Targeting the ubiquitin-proteasome system is revolutionizing disease modeling, inflammation research, and cancer therapeutics. This in-depth article explores the biological rationale for inhibiting the Ubiquitin-Activating Enzyme (E1) with PYR-41, synthesizes the latest mechanistic and translational data, and provides actionable strategies for researchers seeking to bridge basic science and therapeutic innovation. By contextualizing recent findings in viral immunoevasion and proteasome-mediated protein degradation, and contrasting PYR-41 with current tool compounds, we lay out a visionary roadmap for the next generation of ubiquitination research.

• MLN2238: Advancing Proteasome Inhibition for Stress Pathw...

  2026-01-18

  Explore how MLN2238, a potent reversible 20S proteasome β5 subunit inhibitor, enables cutting-edge research into proteotoxic stress responses, apoptosis induction in hematologic malignancies, and NF-κB pathway suppression. This article offers a unique systems biology perspective, bridging molecular mechanisms with translational applications in bortezomib-resistant contexts.

• PYR-41 and E1 Enzyme Inhibition: Unraveling Ubiquitin-Dri...

  2026-01-17

  Explore how PYR-41, a selective inhibitor of Ubiquitin-Activating Enzyme E1, advances ubiquitin-proteasome system inhibition and reshapes NF-κB signaling research. This in-depth article uniquely connects E1 inhibition to immunological mechanisms and emerging cancer therapeutic strategies.

• MG-262 (Z-Leu-Leu-Leu-B(OH)2): A Potent Reversible Protea...

  2026-01-16

  MG-262 (Z-Leu-Leu-Leu-B(OH)2) is a reversible, cell-permeable proteasome inhibitor with nanomolar potency. This agent enables precise dissection of the ubiquitin-proteasome system and apoptotic signaling. Its robust selectivity and quantitative performance support advanced research in cancer, inflammatory, and neurodegenerative disease models.

• Epoxomicin: Selective 20S Proteasome Inhibitor for Precis...

  2026-01-16

  Epoxomicin stands as the gold standard for selective, irreversible proteasome inhibition, empowering researchers to probe the ubiquitin-proteasome pathway with unmatched precision. This guide unpacks robust protocols, advanced applications, and troubleshooting strategies to maximize reproducibility and experimental insight with APExBIO’s Epoxomicin.

• Strategically Targeting the Ubiquitin-Proteasome System: ...

  2026-01-15

  This thought-leadership article dissects the mechanistic role and translational promise of PYR-41, a selective inhibitor of Ubiquitin-Activating Enzyme (E1), in protein degradation pathway research. By integrating recent mechanistic insights, experimental benchmarks, and emerging applications in inflammation and viral immune evasion, we provide translational researchers with a strategic roadmap to harness E1 inhibition for advancing basic discovery and preclinical innovation. The article contextualizes PYR-41 within the broader landscape of ubiquitin-proteasome system tools, highlights its unique ability to modulate NF-κB signaling and apoptosis, and proposes high-impact research avenues in cancer therapeutics and infectious disease models—demonstrating why PYR-41 from APExBIO stands as a next-generation probe for transformational science.

• Disrupting Protein Homeostasis and Rewiring ER Quality Co...

  2026-01-15

  CB-5083, a potent and orally bioavailable p97 inhibitor from APExBIO, offers transformative capabilities for translational researchers investigating cancer cell apoptosis, protein degradation pathways, and ER-driven disease mechanisms. This thought-leadership article unpacks the mechanistic underpinnings of p97 inhibition, showcases experimental validation and emerging clinical relevance, and charts a strategic course for integrating CB-5083 into advanced cancer and metabolic research—drawing on recent discoveries about ER lipid-protein interplay and protein quality control.

• MG-262: Applied Workflows for Reversible Proteasome Inhib...

  2026-01-14

  MG-262 (Z-Leu-Leu-Leu-B(OH)2) stands out as a potent, reversible, and cell-permeable proteasome inhibitor, enabling precise dissection of protein degradation pathways in cell-based and in vivo models. Its unique mechanistic profile empowers advanced studies in apoptosis, cell cycle regulation, and disease modeling—especially where selectivity and reversible inhibition are critical.

• Bortezomib (PS-341): Practical Solutions for Reliable Apo...

  2026-01-14

  This article addresses real-world laboratory challenges in cell viability and apoptosis assays, providing evidence-based strategies for using Bortezomib (PS-341) (SKU A2614) as a reliable, reversible proteasome inhibitor. Scenario-driven Q&A blocks guide biomedical researchers and technicians through optimized experimental design, troubleshooting, and vendor selection, ensuring reproducible results and robust data quality.

8617 records 31/575 page Previous Next First page 上5页 3132333435 下5页 Last page